EcoDrugPlus

Adrenoceptor Beta 1

Ensembl ID : ENSPSNG00000018494
Gene Symbol: ADRB1
3 Cross references
161 Possible Orthologues:

Adrenoceptor Beta 2

Ensembl ID : ENSPSNG00000019879
Gene Symbol: ADRB2
3 Cross references
263 Possible Orthologues:

Advanced Glycosylation End-Product Specific Receptor

Ensembl ID : ENSPSNG00000015846
Gene Symbol: AGER
3 Cross references
169 Possible Orthologues:

Alcohol Dehydrogenase 5 (Class Iii), Chi Polypeptide

Ensembl ID : ENSPSNG00000019392
Gene Symbol: ADH5
2 Cross references
399 Possible Orthologues:

Alcohol Dehydrogenase Class-3-Like

Ensembl ID : ENSPSNG00000015897
Gene Symbol: LOC116759242
2 Cross references
397 Possible Orthologues:

Aldo-Keto Reductase Family 1 Member B

Ensembl ID : ENSPSNG00000010307
Gene Symbol: AKR1B1
3 Cross references
427 Possible Orthologues:

Alpha Glucosidase

Ensembl ID : ENSPSNG00000020528
Gene Symbol: GAA
3 Cross references
234 Possible Orthologues:

Amine Oxidase Copper Containing 1

Ensembl ID : ENSPSNG00000006819
Gene Symbol: AOC1
1 Cross references
230 Possible Orthologues:

Amine Oxidase Copper Containing 3

Ensembl ID : ENSPSNG00000018919
Gene Symbol: AOC3
3 Cross references
322 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSPSNG00000014377
Gene Symbol: APP
3 Cross references
276 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSPSNG00000013551
Gene Symbol: AR
1 Cross references
277 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSPSNG00000012278
Gene Symbol: AGTR1
1 Cross references
207 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).